Ensysce Biosciences Inc Ordinary Shares ENSC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ENSC is a good fit for your portfolio.
News
-
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
-
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
-
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
-
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
-
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
-
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
-
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
-
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Trading Information
- Previous Close Price
- $0.61
- Day Range
- $0.54–0.61
- 52-Week Range
- $0.53–7.20
- Bid/Ask
- $0.56 / $0.61
- Market Cap
- $4.32 Mil
- Volume/Avg
- 20,492 / 209,996
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 8
- Website
- https://www.ensysce.com
Valuation
|
Metric
|
ENSC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ENSC
|
|---|---|
Quick Ratio | 0.37 |
Current Ratio | 0.69 |
Interest Coverage | −29.02 |
Quick Ratio
ENSC
Profitability
|
Metric
|
ENSC
|
|---|---|
Return on Assets (Normalized) | −230.43% |
Return on Equity (Normalized) | −2,935.45% |
Return on Invested Capital (Normalized) | −787.73% |
Return on Assets
ENSC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Htyhkgkn | Cgccc | $559.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rrgxprd | Mfgzh | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rcwcmfyrd | Fqgxmjd | $103.3 Bil | |
MRNA
| Moderna Inc | Bnyyqbc | Cfh | $48.1 Bil | |
ARGX
| argenx SE ADR | Nfhgtwp | Fyj | $23.1 Bil | |
BNTX
| BioNTech SE ADR | Dcjdqkq | Xtyw | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gtdmqgdy | Mbsknbx | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dlygkbj | Gwqmhj | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Clfgpttyz | Qzqys | $12.7 Bil | |
INCY
| Incyte Corp | Swzpdrv | Xmdkvfw | $11.9 Bil |